HAB Pharma and Signature Phytochemicals have completed a strategic merger through a slump sale, bringing both companies under a single consolidated entity.
Finalized in March 2026, the merger was undertaken to streamline operations, harmonize corporate systems, and strengthen governance, positioning the combined company for future growth and operational efficiency. The consolidated turnover is approximately ₹600 crore after accounting for intercompany sales.
HAB Pharmaceuticals is commissioning two new manufacturing plants: a sterile facility focused on semaglutide, prefilled syringes, injectables, vials and lyophilized products and a fully automated closed-loop oral solid dosage (OSD) plant. Both plants are expected to commence commercial production by August 2026. These facilities will enhance the company’s capacity to meet growing demand, support regulatory approvals, and expand its presence in Southeast Asia, Latin America, and Africa, where it has already been audited by regulators in Uganda, Tanzania, and Iraq.
“This merger marks a pivotal moment for our company,” said Mr. Saurabh Agarwal, Director at HAB Pharma. “By consolidating our operations with Signature and strengthening our manufacturing capacities, we are now positioned for substantial growth. Our focus on innovation, niche products, and increasing our export and R&D capabilities will solidify the company’s position in the pharmaceutical industry, differentiating us through a diversified portfolio and a rapid go-to-market strategy. The new plants will provide us with the capacity to meet rising demand for complex and high-quality pharmaceutical products. Together, we will continue to lead in biologics, personalized medicine, and specialty generics by leveraging advanced R&D and innovative drug delivery systems
Ms. Urvee Garg, Director at HAB Pharma, also shared her thoughts on the merger and the company’s growth trajectory, “This merger represents the next chapter in HAB Pharma’s growth story. We are focused on creating a more cohesive organization that can better serve both our domestic and international markets. With a solid foundation in manufacturing, a commitment to quality, and a focus on affordability, we are confident that HAB Pharma will continue to thrive and deliver innovative healthcare solutions across the world.”
HAB Pharma aims to scale its revenues to ₹2,500-3,000 crore by 2030, driven by expanded manufacturing capacity, strengthened R&D capabilities, and a focus on off-patent molecules and complex dosage forms. The company continues to build on its legacy of providing affordable, high-quality medicines, particularly for general practitioners in India, while enhancing its presence in international markets.
